Clinical Trial Update: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 trial update reporting completion of daratumumab monotherapy in previously untreated patients with Stage 3B light chain (AL) amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Stichting European Myeloma Network | Conditions: Light Chain (AL) Amyloidosis, Stage 3B | Phase 2 | Status: COMPLETED